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Abstract:  Safflower (Carthamus tinctorius L.) seeds are used as a folk medicine to 
enhance bone formation or to prevent osteoporosis in Korea. Therefore, the methanolic 
extract of safflower seeds (MESS) containing high mineral content, such as calcium (Ca), 
potassium (K) and phosphorous (P), was evaluated for the role on  osteoblast (Ob) 
markers of Sprague-Dawley rats. In serum of 3 to 11 weeks (wks) old rats, both 
osteocalcin (OC) content and bone-specific alkaline phosphatase (B-ALP) activity 
increased to their maximum levels in 4-7 wks. Hence, 3 wks old rats were selected for 8 
wks oral treatment of MESS, resulted in the significant increase of Ob markers in serum 
such as OC content (4-8 wks), B-ALP activity (1-2 wks) and insulin-like growth factor I 
(IGF-I) level (1 wk), and the growth parameter such as the length of femur (2-8 wks) and 
tibia (4 wks). On the basis of Pearson’s correlation coefficient, there were a moderate 
correlation between OC and B-ALP at 8 wks, a low correlation between OC and IGF-I at 
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1, 4 and 8 wks, a moderate correlation between OC and femur length at 1, 2 and 8 wks, 
and a moderate correlations between OC and tibia length at 1 and 8 wks of MESS-treated 
groups. The result reveals that the changes of OC correlated at low to moderate level with 
the changes of B-ALP activity, IGF-I content and femur and tibia length in the MESS-
treatment period. On the other hand, there were a strong correlation between IGF-I and 
femur length at 2 wks and moderate correlation between IGF-I and tibia length at 1, 2 and 
8 wks of MESS-treated groups. Therefore, the effect of MESS on bone formation likely 
appears to be mediated by IGF-I at the early stage of treatment.  
 
Keywords:  Safflower (Carthamus tinctorius L.) seeds, methanolic extract, osteoblast 
activities, osteocalcin, bone-specific alkaline phosphates, IGF-I. 
 
 
1. Introduction  
 
Osteoblast (Ob) plays a critical role in bone formation through the proliferation and differentiation 
[1]. The latter is referred as obvious bone rigidity and strength with some degree of elasticity. Ob is the 
bone-forming cells responsible for the production of the bone matrix constituents, mainly type I 
collagen which becomes mineralized by deposition of Ca and non-collagenous protein. About 1% of 
the matrix is made up of osteocalcin (OC). OC plays a role in Ca binding and stabilization of 
hydroxyapatite in the matrix and/or regulation of bone formation [2]. Serum OC levels are higher in 
individuals undergoing rapid bone loss and lower in those with reduced bone turnover [3]. Bone-
specific alkaline phosphatase (B-ALP) is a non-collagenous protein secreted by Ob, which is essential 
for bone mineralization [2]. Increased B-ALP levels in serum has been observed in conditions such as 
postmenopause, ovariectomy and osteoporosis in women [4], rapid bone loss [5] and fracture risk [6, 
7]. OC and B-ALP levels in humans are relatively high during growth but lower after skeletal growth 
has brought to an end. Both levels also remain low in premenopausal women and middle-aged men, 
and then increase in older individuals including elderly men and post-menopausal women [8].  
Serum insulin-like growth factor I (IGF-I) - a predominant growth factor produced by Ob is a 
determinant of bone size and mass in postnatal life [9]. IGF-I mediates the stimulatory effect of growth 
hormone (GH) on longitudinal bone growth [10] and also required for the anabolic actions of 
parathyroid hormone on bone [11]. Earlier studies demonstrated that animal dietary supplementation 
with dried plum, a rich source of phenolic and flavonoid compounds prevents the detrimental effects of 
ovarian hormone deficiency on bone density and trabecular structure [12] and reversed bone loss in the 
same model [13]. It has been suggested that the protection in ovarian hormone deficiency appears to be 
resulted from enhanced bone formation mediated through IGF-I [14]. In addition, the dried plum 
prevents osteopenia in androgen deficient male rats, and these improvements may be partly due to 
decrease in osteoclastogenesis via stimulation of bone formation mediated by IGF-I [15]. 
Safflower (Carthamus tinctorius L.) is a member of the family Compositae or Asteraceae. Its seeds 
contain a natural pigment known as carthamin derived from precarthamine by enzymatic reaction [16]. 
Traditionally, safflower has been used for purgative and alexipharmic effects, as well as in a medicinal 
oil to promote sweating and cure fevers in the Middle East, India and Africa [17]. In China, it is Int. J. Mol. Sci. 2009, 10                           
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widely used in the treatment of many disorders and diseases including menstrual problems, 
cardiovascular disease, pain and swelling associated with trauma [18], chronic and atrophic gastritis 
[19], ankyloenteron [20], rheumatism [21], and chronic nephritis [22]. Especially, it has been used 
mainly for the treatment of cardiovascular disease because it invigorates the circulation and reduces 
blood cholesterol levels [18]. In Korea, the safflower seed extracts have traditionally been used for the 
treatment of blood stasis, the promotion of bone formation and the prevention of osteoporosis [23]. 
Safflower seeds might also have a potentiality to use as a drug for bone regeneration [24], Ob 
mineralization [25] and regeneration of periodontal defect [26]. In addition, safflower seeds have a 
protecting effect on bone loss caused by estrogen deficiency without substantial effect on the uterus 
[27]. A Korean herbal formulation, Gami-Honghwain, is comprised of crude ingredients from 
safflower seeds and hominis placenta. The Gami-Honghwain inhibited the elevated production of IL-
1β which is implicated in the osteoporosis [28] and stimulation of the proliferation, differentiation and 
mineralization of osteoblastic MC3T3-E1 cells [29].  
There are reports about chemical components of the safflower. Its leaves contain eight flavonoids, 
some of which showed potent antioxidant activities [30]. Its seeds also contain numerous polyphenolic 
compounds such as lignans, glucosides, flavonoids and serotonins. The chemical structures and 
antioxidant properties of these compounds have been characterized [31]. These compounds, termed 
phytoestrogens, are known to have weak estrogenic or antiestrogenic activity towards mammals [32]. 
However, no information is available on mineral content of safflower seeds. The aim of present study 
was to determine the mineral content in methanolic extract of safflower seeds (MESS) and examine its 
biological effects on rats’ Ob cells by the analysis of biochemical and morphological parameters. It 
will also provide the scientific basis for the usage of safflower seeds in the treatment of bone formation 
related with health.  
 
2. Results and Discussion   
 
2.1. Comparison of mineral content between aqueous and methanolic safflower seed extracts 
 
Bone is a connective tissue mainly composed of organic and inorganic materials like collagen and 
the inorganic mineral hydroxyapatite, both of which combine to allow bone to be flexible and strong. 
The organic components include cells, as well as fibers which are similar to those that make up other 
connective tissues such as cartilage, while the inorganic minerals constitute predominantly Ca, P, 
CO3
2- and minor ingredients [33]. To determine the mineral content in safflower seeds, we used high-
throughput ICP-MS, and this approach included the quantification of ten elements. In the aqueous 
extract from safflower seeds, there are K (2.306 μg/g), P (1.043 μg/g), Mg (0.474 μg/g), Al (0.175 
μg/g), Fe (0.100 μg/g), Ca (0.075 μg/g), Zn (0.070 μg/g), Na (0.066 μg/g), Cu (0.055 μg/g) and Sr 
(0.022 μg/g). In the MESS, there are Ca (3.752 μg/g), K (1.313 μg/g), P (1.161 μg/g), Na (0.177 μg/g), 
Fe (0.170 μg/g), Zn (0.042 μg/g), Mg (0.023 μg/g), Al (0.019 μg/g), Cu (0.015 μg/g) and Sr (0.002 
μg/g). It is observed that Ca, K and P are orderly high in methanolic extract, while K, P and Mg are 
orderly high in aqueous extract (Table 1).  
Ca is necessary for many processes in the body, including contraction of muscles, nerve function, 
blood coagulation, and cell division. Only 1% of the Ca in the body is available in circulation for these Int. J. Mol. Sci. 2009, 10                           
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functions, while the remaining 99% is housed in the bones. Osteoclast breaks down bone and converts 
the Ca salts into a soluble form which is easily circulated in the blood. Eventually, Ca salts are 
deposited on the surface of the bone matrix. If enough Ca is not available, bones cannot be properly 
mineralized [34]. K salts may benefit bone health by providing an anion that can be metabolized 
completely to carbon dioxide, or influence Ca excretion directly [35]. In addition, dietary K intake 
may exert a modest influence on markers of bone health, which over a lifetime may contribute to a 
reduced risk of osteoporosis [36]. Bone stores most P within the body to mineralize its matrix and 
serve as a mineral source. Inorganic phosphate plays a critical role in the maintenance of mineralized 
tissues and signaling in the intracellular environment [37]. In the present investigation, the MESS was 
selected for further analysis because it has high Ca, K and P contents.  
 
Table 1. Mineral contents of extracts from Carthamus tinctorius. 
Elements 
Contents (μg/g) 
W
1) M
2) 
Al 0.175  0.019 
Ca 0.075  3.752 
Cu 0.055  0.015 
Fe 0.100  0.170 
K 2.306  1.313 
Mg 0.474  0.023 
Na 0.066  0.177 
P 1.043  1.161 
Sr 0.002  0.002 
Zn 0.070  0.042 
W
1) = Distilled water extract of Carthamus tinctorius.   
M
2) = Methanol extract of Carthamus tinctorius.   
 
2.2. Dependence of OC content and B-ALP activity on  aging of rats 
 
Although the precise function of OC and B-ALP are not clear, they are known as serum markers 
reflecting Ob activities including bone formation and turnover [38, 39]. Ob markers associated with 
aging, like OC content and B-ALP activity in serum of rats aged from 3 to 11 weeks (wks) were 
analyzed. Figure 1 illustrates the relationship between age and OC or B-ALP in rats. The serum OC 
content (ng/mL) of rats aged 3, 4, 5, 6, 7, 8 and 11 wks old were 88.85±3.54, 91.45±2.06, 85.27±3.41, 
95.40±2.79, 101.97±3.13, 97.88±3.69 and 66.80±1.96. The B-ALP activities (IU/l) in rats aged 3, 4, 5, 
6, 7, 8 and 11 wks old were 412.83±42.81, 590.88±30.97, 490.44±44.88, 575.82±16.62, 712.92±59.62, 
440.33±51.39 and 221.0±16.57. The results showed the normal variation in OC and B-ALP levels of 
rats and also revealed the age influence on this variation. OC and B-ALP levels in serum of rats are Int. J. Mol. Sci. 2009, 10                           
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positively correlated with each other, and both markers appeared as bimodal pattern. The 1
st peak was 
observed at 4 wks old and the 2
nd peak was at 7 wks of age. After this time, there was a steep drop in 
serum B-ALP activity from 7 to 11 wks and its reduction rate was approximately 67%. However, there 
was a slight decline in serum OC content from 7 to 11 wks of age and its reduction rate was 
approximately 30%. This tendency is consistent with previous reports in that the rats showed the 
highest B-ALP activity from 5 to 7 wks old [40] and the rapid decrease of B-ALP activity from 8 to 12 
wks old [41].  
 
Figure 1. Changes of osteocalcin content (upper panel) and bone-specific alkaline 
phosphatase activity (lower panel) in serum of Sprague-Dawley rats by age groups. Mean 
of measurement values indicated on the line. 
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2.3. Effects of methanolic safflower seed extracts on OC contents and B-ALP activities  
 
Compared with control rats, there were no significant differences in the increase of OC content of 
rats at 1 (4 wks old) and 2 (5 wks old) wks after oral treatment with MESS. However, there were 
significant differences (P < 0.05) at 4 (7 wks old) and 8 (11 wks old) wks after MESS treatment by the 
increase of 10.2% and 8.1%, respectively (Figure 2). Rats at 4 wks after MESS treatment showed the 
highest OC contents. These results suggest that the treatment with MESS induce rats’ Ob cells, thereby 
increase the secretion of OC from 4 to 8 wks after oral administration.  
 
Figure 2. Concentration of osteocalcin and bone-specific alkaline phosphatase in serum 
after oral administration of Carthamus tinctorius extract. 
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Values are mean ± S.E. *Statistically significant difference between experimental and control 
group by Student's t-test at 0.05. C: control group and T: administration of Carthamus tinctorius 
was started at age of 3 wks old. 
 
On the other hand, there were significant differences (P < 0.05) in B-ALP activity of rats 
administered orally with MESS at 1 (24.5%) and 2 (36.8%) wks but no significant differences at 4 and 
8 wks after MESS treatment (Figure 2). The maximum B-ALP activity of rats treated with MESS Int. J. Mol. Sci. 2009, 10                           
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appeared at 1
 wk and the maximum percentage of increase appeared at 2 wks, while the peak activity 
of control rats appeared at 4 wks. Similarly, it has been reported that phenolic glycosides isolated from 
MESS increase the ALP activity of human Ob-like cells [42]. B-ALP is known as a biomarker for Ob 
differentiation and its upregulation occurs at the middle stage of differentiation [43]. In the present 
study, MESS stimulates Ob to synthesize of B-ALP at the early stage of treatment. However, we 
observed a low correlation between OC and B-ALP of MESS-treated groups at 1, 2 and 4 wks (r = 
0.1054, r = 0.3015 and r = –0.3973, respectively) and a moderate correlation at 8 wks (r = –0.5955). 
 
2.4. Effect of methanolic safflower seeds extract on serum IGF-I levels and long bone growth 
 
Serum IGF-I levels in both control and MESS-treated rats increased with age and reached the 
highest level at 4 wks during the experimental period. A significant increase of IGF-I level (7.52%) 
was observed at 1 wk after MESS treatment, and IGF-I was slightly higher in MESS-treated rats than 
in control throughout the experimental period (Figure 3). In earlier studies, IGF-I increased the number 
and proliferation of Ob cells, stimulated bone formation, maintained bone mass, and acted as a local 
proliferation and maturation factor for chondrocytes in the growth plate, which is essential for 
longitudinal bone growth [44]. IGF-I is abundant in liver and hepatic synthesis of IGF-I could account 
for the known turnover of this peptide in the circulation [45]. Biochemical markers of bone formation 
and bone resorption correlated with circulating GH and IGF-I levels, suggesting that GH and liver-
derived IGF-I may have direct effects on Ob cell in modulating turnover [46]. Recently, the role of 
liver-derived IGF-I have been questioned in relation to effects on bone metabolism [47, 48]. The 
concentration of free IGF-I and -II in normal human serum is less than 0.5% of the total concentration 
of the IGF [49]. Despite the fact that this component is crucial in the feedback regulation of pituitary 
GH secretion and endocrine action of IGF-I on target tissues [50].  
To determine MESS effect on the bone length, we measured the length of rats’ femurs and tibias at 
1-8 wks after treatment. There were significant increases (P < 0.05) in femur length at 2 (3.04%), 4 
(5.40%) and 8 (4.28%) wks after MESS administration (Figure 3). We observed a strong correlation 
between IGF-I and femur length of MESS-treated groups at 2 wks (r = 0.7005). However, there was a 
low correlation at 1 wk (r = 0.2852) and no correlation at 4 and 8 wks (r = 0.0031 and r = 0.0980, 
respectively). In addition, there was a significant increase (P < 0.05) in tibia length at 4 (4.07%) wks 
after MESS administration (Figure 3) but a low correlation between IGF-I and tibia length at 4 wks (r 
= 0. 1955). On the contrary, there was no significant increase in tibia length at 1, 2 and 8 wks after 
MESS administration but a moderate correlation between IGF-I and tibia length at 1, 2 and 8 wks (r = 
–0.6014, r = –0.5045 and r = 0.5000, respectively). In earlier studies, there is a positive correlation 
between serum IGF-I levels and bone mass in mice and humans [51, 52] and also bone mineral 
content, bone mineral density and femur length [9]. During the active bone growth period (3 to 11 
wks), rats fed with MESS showed the elongation of the femur and tibia, which represents an effect on 
bone modeling (affects size and shape of whole bone and occurs of long time period, for example 
skeletal maturity about 18 years in human) but not bone remodeling. Therefore, the present study 
indicates that the effect of MESS on bone formation likely appears to be mediated by IGF-I at the 
early stage of treatment. Int. J. Mol. Sci. 2009, 10                           
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Figure 3. Concentration of IGF-I in serum and length of femur after oral administration of 
Carthamus tinctorius extract. 
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Values are mean ± S.E. *Statistically significant difference between experimental 
and control group by Student's t-test at 0.05. C: control group and T: administration 
of Carthamus tinctorius was started at age of 3 weeks old.  Int. J. Mol. Sci. 2009, 10                           
           
 
300
Moreover, during this period of time (bone modeling) Ob markers are expected to be increased, but 
we observed a low correlation between OC and IGF-I of MESS-treated groups at 1, 4 and 8 wks (r = 
0.2059, 0.2043 and 0.1005, respectively) but not at 2 wks (r = – 0.0003). A moderate correlation 
between OC and femur length of MESS-treated groups was observed at 1, 2 and 8 wks (r = – 0.4998/ 
0.5000 and– 0.5980, respectively) and a low correlation at 4 wks (r = – 0.1063). A moderate 
correlation was also observed between OC and tibia length for MESS treated groups at 1 and 8 wks (r 
= – 0.4010/– 0.4024), and a low correlation at 2 wks and 4 wks (r = – 0.2985/– 0.2994). Though we 
could not predict clearly through Pearson’s correlation coefficient, the percentage changes in OC 
content were not related to the changes of B-ALP activity, IGF-I content and femur and tibia length. 
However, the changes of OC correlated at low and moderate levels to the changes of B-ALP activity, 
IGF-I content and femur and tibia length during the experimental period.  
 
3. Experimental Section 
 
3.1. Preparation of safflower seeds extract and analysis of mineral content 
 
Safflower seeds were collected from a local medicinal market in Daejeon, Korea and homogenized 
by a crusher to obtain a crude powder, 300 g of which was extracted as described in Figure 4. In the 
final step of methanolic extraction, the aqueous methanol layer was evaporated under reduced pressure 
using a rotary evaporator at 40-50˚ C and freeze-dried as a powder. Another 300 g of powder was 
decocted in a round flask with distilled water (1:10, w/v) at 60˚ C for 3 h, then filtered using No. 40 
Whatman filter paper to remove particulate matter and evaporated in a rotary evaporator under the 
same conditions mentioned above. The yields of crude methanol and water extracts were about 30 and 
25 g, respectively. Each extract was heated at 55 ˚ C for 20 h, and then dissolved in 6 N HCl 
containing 1% LiCl3 to determine mineral content using an inductively coupled plasma mass 
spectrophotometer (ICP-MS Elan 6000, Perkin-Elmer, USA) as described in the manufacturer’s 
directions.  
 
3.2. Experimental animals and administration of extract 
 
Three wks old male Sprague-Dawley rats weighing 34.2±2 g were selected and housed in 
polycarbonate cages under a 12 h light/12 h dark cycle at a regulated temperature of 25±1˚ C and 
55±5% humidity. A commercial standard pellet diet and water was available ad libitum throughout the 
experimental period. To compare OC contents, B-ALP activities and IGF-I contents between non-
treated control group and treated group, six rats were used and administered once a day orally with 
MESS at a dose of 350 mg/kg body weight using an oral sonde (Natusme Seisakusho, Tokyo,
 Japan) 
for 8 wks. The dose was based on previous a report in that no toxic effect was observed from serum 
and urine indexes after feeding the safflower seed diet [53]. At the end of the oral administration 
period 1-8 wks (corresponding age 4-11 wks old), the rats were fasted for 12 h and then immediately 
sacrificed using ether. After confirming the deep anesthesia, heart puncture and orbital bleeding were 
performed and blood was collected from the main artery. Serum was separated by centrifugation at 
3,000 rpm for 15 min. The schedules and procedures were performed in the experimental animal Int. J. Mol. Sci. 2009, 10                           
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handling facility at the Department of Biology & Medicinal Science, Pai Chai University, in 
compliance with ethical regulations. 
 
Figure 4.  Flow chart showing the methanolic extraction from safflower seeds. 
 
 
3.3. Biochemical analysis of serum 
 
Serum OC content was determined using a Rat Osteocalcin EIA kit (Bioquote Limited, UK) as 
described in the manufacturer’s directions. Two OC antibodies were employed, each directed toward 
the N or C-terminal OC molecule. B-ALP activity in serum was determined using a commercially 
available ELISA kit (Alkphase B
TM, Metra Biosystema Inc., CA, USA). Serum IGF-I was measured 
by a double antibody immunoradiometric assay (IRMA) using Non Extraction IGF-I Bridge Kit 
(Adaltis, Italy) as described in manufacturer’s directions. The first antibody is immobilized to the 
inside wall of the tubes (anti-IGF-I-coated tubes) and the second antibody is radiolabelled for detection 
[anti-IGF-I- (I
125)]. The radioactivity was measured in a gamma counter for 1 min and determined the 
net counts per min (CPM).  
 
3.4. Measurement of long bone growth 
 
To determine long bone growth, we used x-rays. The length of femurs and tibias in all treatment 
groups was measured three times to 0.01 cm using a calibrated digital Vernier caliper.  
 Int. J. Mol. Sci. 2009, 10                           
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3.5. Statistical analysis 
 
Data were expressed as the mean ± SE calculated from the specified numbers of determination and 
analyzed with SPSS 15.0 (SPSS, USA) to determine the significance of effect of safflower seed extract 
on OC, B-ALP, IGF-I and bone growth. Data comparisons were made by the Student's t-test.   
Pearson´s correlation coefficients were used to test the association of OC with other parameters like B-
ALP activity and IGF-I content in serum and femur and tibia length. All values less than 0.05 (p<0.05) 
were considered statistically significant.  
 
4. Conclusions  
 
MESS contains a high mineral content, such as Ca, K and P. Notable elevation was observed on 
IGF-I level at 1 wk, followed by a significant and maximum increase of B-ALP at 2 wks and OC at 4 
wks after the administration of MESS into rats. The significant elongation of the femur was observed 
at 2, 4 and 8 wks after treatment with MESS, suggesting that the MESS effect on bone formation likely 
appear to be mediated by IGF-I at the early stage of treatment. However, OC content change might be 
less associated with the changes of B-ALP activity, IGF-I content, and femur and tibia length. In 
addition, MESS has no cytotoxicity under this experimental condition, hence, it can be used as a 
potential alternative to enhance bone formation.  
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